Mosapramine

Mosapramine is an atypical antipsychotic used in Japan for the treatment of schizophrenia. It was approved for use in 1991. Mosapramine acts as a D2 receptor antagonist and also has high affinity for the sigma receptors, possibly playing a role in its antipsychotic effects.

Pharmacology

Mosapramine is classified as an atypical antipsychotic due to its distinct pharmacology; it has a high affinity for the D2, D3, and D4 dopamine receptors, and also for the sigma receptors. The drug has a lower affinity for the serotonin 5-HT2A and 5-HT2C receptors.

Clinical Use

In Japan, mosapramine is used for the treatment of schizophrenia. It has been found to be effective in treating both positive and negative symptoms of the disorder. The drug is usually well-tolerated, with side effects similar to those of other atypical antipsychotics.

Side Effects

Common side effects of mosapramine include drowsiness, dizziness, and dry mouth. Less common side effects can include tachycardia, hypotension, and extrapyramidal symptoms such as tremor and akathisia. Rare but serious side effects can include neuroleptic malignant syndrome and tardive dyskinesia.

See Also

• Atypical antipsychotic
• Dopamine receptor
• Sigma receptor
• Schizophrenia

Mosapramine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski